Nexalin Technology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.9M
- Price
- $0.4012
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.35%
- Volume
- 678.9K
Quote data as of 6:15 AM ET
About
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Quick stats
Shares outstanding21.5M
Computed float16.5M
Float sourceUnknown
Cash runway (months)2.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001527352
Websitehttps://www.nexalin.com
AI Summary
AI-generated16d agostandardbullishclinical trialNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
An investigator on Nexalin’s Brazilian clinical study received the Young Researcher Award at the BRAIN 2026 congress for research evaluating the company’s proprietary DIFS platform.
The awarded study demonstrated significant, durable improvement in sleep quality for patients with comorbid anxiety using the 15 mA, 77.5 Hz device over 20 sessions.
Management emphasized that this independent scientific recognition strengthens the credibility of the technology as the company prepares for the commercial launch of its SYNC device in Brazil.
Red flags
- Award does not constitute regulatory approval or endorsement